share_log

8-K: Applied DNA Announces Fourth Quarter and Fiscal Year 2024 Financial Results, Announces Strategic Restructuring to Prioritize the Manufacture of Critical Starting Materials for Genetic Medicines

8-K: Applied DNA Announces Fourth Quarter and Fiscal Year 2024 Financial Results, Announces Strategic Restructuring to Prioritize the Manufacture of Critical Starting Materials for Genetic Medicines

8-K:Applied DNA公佈第四季度和2024財年財務業績,宣佈戰略重組,優先生產基因藥物的關鍵起始材料
美股SEC公告 ·  2024/12/17 13:14

Moomoo AI 已提取核心訊息

Applied DNA Sciences announced Q4 and FY2024 results, along with a strategic restructuring to prioritize manufacturing critical materials for genetic medicines. The company is pursuing divestiture of its CertainT platform and targeting 15% operating expense reductions by Q2 FY2025.Q4 revenues were $813,000, up from $780,000 in Q4 FY2023. FY2024 revenues fell to $3.4 million from $13.4 million, due to decreased COVID-19 testing demand. Net loss for FY2024 was $7.1 million. Cash and equivalents totaled $6.4 million as of September 30, 2024, with an additional $5.8 million raised in October.The company promoted Judith Murrah to President and Clay Shorrock to President of LineaRx subsidiary. It expects to complete its GMP manufacturing facility by January 9, 2025, with $4-16 million annual revenue capacity. GMP production for existing customers' clinical trials is anticipated in H1 2025.
Applied DNA Sciences announced Q4 and FY2024 results, along with a strategic restructuring to prioritize manufacturing critical materials for genetic medicines. The company is pursuing divestiture of its CertainT platform and targeting 15% operating expense reductions by Q2 FY2025.Q4 revenues were $813,000, up from $780,000 in Q4 FY2023. FY2024 revenues fell to $3.4 million from $13.4 million, due to decreased COVID-19 testing demand. Net loss for FY2024 was $7.1 million. Cash and equivalents totaled $6.4 million as of September 30, 2024, with an additional $5.8 million raised in October.The company promoted Judith Murrah to President and Clay Shorrock to President of LineaRx subsidiary. It expects to complete its GMP manufacturing facility by January 9, 2025, with $4-16 million annual revenue capacity. GMP production for existing customers' clinical trials is anticipated in H1 2025.
Applied DNA Sciences公佈了2024財年第四季度和全年業績,以及一項戰略重組,以優先考慮製造基因藥物的關鍵材料。公司正在尋求剝離其Certaint平台,並目標在2025財年第二季度前減少15%的運營支出。第四季度營業收入爲813,000美元,較2023財年第四季度的780,000美元有所增長。2024財年的營業收入從1340萬美元減少至340萬美元,主要由於COVID-19檢測需求減少。2024財年的淨虧損爲710萬美元。截至2024年9月30日,現金及等價物總計爲640萬美元,10月份又籌集了580萬美元。公司晉升Judith Murrah爲總裁,Clay Shorrock爲LineaRx子公司的總裁。預計在2025年1月9日前完成其GMP製造設施,年營業收入能力爲400-1600萬美元。預計在2025年上半年爲現有客戶的臨牀試驗進行GMP生產。
Applied DNA Sciences公佈了2024財年第四季度和全年業績,以及一項戰略重組,以優先考慮製造基因藥物的關鍵材料。公司正在尋求剝離其Certaint平台,並目標在2025財年第二季度前減少15%的運營支出。第四季度營業收入爲813,000美元,較2023財年第四季度的780,000美元有所增長。2024財年的營業收入從1340萬美元減少至340萬美元,主要由於COVID-19檢測需求減少。2024財年的淨虧損爲710萬美元。截至2024年9月30日,現金及等價物總計爲640萬美元,10月份又籌集了580萬美元。公司晉升Judith Murrah爲總裁,Clay Shorrock爲LineaRx子公司的總裁。預計在2025年1月9日前完成其GMP製造設施,年營業收入能力爲400-1600萬美元。預計在2025年上半年爲現有客戶的臨牀試驗進行GMP生產。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息